BofA analyst Jason Gerberry raised the firm’s price target on Harmony Biosciences (HRMY) to $33 from $31 and keeps an Underperform rating on the shares. The Q4 update was “largely as expected,” though the company did announce a Wakix patent settlement for 2030 entry, the analyst noted. However, six other generic challengers remain with a trial in 2026, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Cautious Outlook: Sell Rating for Harmony Biosciences Due to Pipeline Concerns and Generic Competition Risks
- Harmony Biosciences Reports Strong 2024 Financial Results
- Harmony Biosciences files automatic mixed securities shelf
- Harmony Biosciences Holdings: Strong Financial Performance and Strategic Settlements Drive Buy Rating
- Harmony Biosciences reports Q4 EPS $1.08, consensus 82c